C-ERBB2和MYC mRNA基因表达水平在乳腺癌诊断的临床应用

The Clinical Application of C-ERBB2 and MYC mRNA Expressions in Diagnosis of Breast Carcinoma

目的采用逆转录聚合酶链反应(RT-PCR)检测C-ERBB2和核内原癌基因(c-MYC)在外周血循环肿瘤细胞(circulating tumor cell,CTC)的表达,探讨其在乳腺癌诊断中的应用。方法以β2-actin为内对照,采用RT-PCR检测40例健康体检者、79例乳腺癌、66例良性乳腺疾病和51例其它肿瘤患者外周血CTCs中C-ERBB2和MYC mRNA表达水平。结果外周血CTCs中C-ERBB2和MYC在乳腺癌组和良性乳腺疾病组的表达率比较,差异有统计学意义;在乳腺癌组和其它肿瘤组表达率比较,差异有统计学意义;而良性乳腺疾病组和其它肿瘤组的表达率比较,差异无统计学意义。C-ERBB2和MYC联合检测,可提高对乳腺癌诊断的灵敏度、特异性和一致率。结论 RT-PCR联合检测外周血CTCs的C-ERBB2和MYC基因表达水平,可提高对乳腺癌诊断的特异性,具有操作简便、价格便宜和标本来源容易等优点,可有效辅助诊断乳腺癌。

Objective To explore the clinical application of the expressions of C-ERBB2 and MYC in CTCs in diagnosis of breast carcinoma according to detecting the C-ERBB2 and c-MYC mRNA expressions in the circulating tumor cells by RT-PCR.Methods In internal contrast withβ2-action,the significant differences of the expressions of C-ERBB2 and MYC among the 40-health-people group,the 79-breast-carcinoma group,the 66-benign-breast-disease group and the 51-other-carcinoma group were detected by the RT-PCR.Results 1）There was significant difference in the expression rates of C-ERBB2 and MYC between breast-carcinoma group and the benign disease group;2）There was significant difference in the expression rates of those between the breast-carcinoma group and othercarcinoma group;3）There was no difference of those expression rates between the benign-breast-disease group and the other-carcinoma group.The sensitivity,specificity and concordance rate were improved by combining detection of C-ERBB2 and MYC.Conclusion The specificity of RT-PCR to diagnose the breast cancer can be improved by combining with the detection of the expressions of C-ERBB2 and MYC in CTCs.This combination also can be a useful back-up in diagnosis of the breast cancer because of some advantages,like simple operation,low price,easy sample source and so on.